Gilead Sciences Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One decreased by 21.1% to $15.00M in Q1 2026 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Higher values indicate greater near-term liquidity from the investment portfolio, reducing reliance on external financing.
This represents the portion of the available-for-sale debt securities portfolio that is scheduled to mature within the f...
Consistent with standard treasury management practices for large-cap firms with significant cash reserves.
other_available_for_sale_securities_debt_maturities_with_de2040| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.69B | $1.39B | $1.09B | $953.00M | $1.01B | $999.00M | $1.01B | $1.23B | $79.00M | $19.00M | $15.00M |
| QoQ Change | — | -17.6% | -21.9% | -12.2% | +5.8% | -0.9% | +0.8% | +21.7% | -93.6% | -75.9% | -21.1% |
| YoY Change | — | — | — | -43.5% | -27.5% | -8.0% | +5.7% | +21.6% | — | — | — |